PET imaging targeting GPC3 for liver cancer diagnosis
Official title: Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
Run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · NCT06383520 · Data updated 2026-11-12
This study is testing a new type of PET imaging to see if it can help doctors better diagnose liver cancer in patients who might have it.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | September 30, 2023 |
| Main results expected | August 31, 2025 |
| Study ends | December 2025 |
| Registry record updated | May 14, 2025 |
| Trial ID | NCT06383520 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults with newly diagnosed hepatocellular carcinoma or those with a history of the disease who are willing to participate.
✕Probably not a fit
Patients who are pregnant, lactating, or have acute systemic diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial focuses on the use of PET imaging with a GPC3-specific probe to improve the diagnosis and staging of hepatocellular carcinoma (HCC). Patients with suspected or confirmed HCC, as well as healthy volunteers, will undergo PET/CT imaging to evaluate the pharmacokinetics and efficacy of the imaging agent. The study aims to collect clinical data and imaging results to enhance early detection methods for HCC, which is often diagnosed at an advanced stage. The final diagnosis will be confirmed through histopathological examination of biopsy or surgical specimens.
Why it matters
Potential benefit: If successful, this approach could lead to earlier and more accurate diagnosis of hepatocellular carcinoma, potentially improving patient outcomes.
How similar studies have gone: While traditional imaging methods have limitations, this novel approach using GPC3-targeted PET imaging has not been widely tested, making it a potentially groundbreaking method.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1: Voluntarily participate and the person or their legal representative can sign an informed consent form * 2: Adult patients (18 years of age or older), regardless of gender * 3: Patients with newly diagnosed hepatocellular carcinoma with high clinical suspicion or confirmation (supporting evidence including imaging data and histopathologic examination, etc.) who agree to undergo histopathologic examination (if not performed prior to imaging) or/and 18F-FDG PET imaging * 4: Healthy volunteer * 5: Patients with a history of hepatocellular carcinoma, remission and recurrence after treatment * 6: Willing and able to follow schedule visits, treatment plans and laboratory tests Exclusion Criteria: * 1: Pregnant or lactating patients * 2: The patient or their legal representative is unable or unwilling to sign the informed consent form * 3: Acute systemic diseases and electrolyte disorders * 4: Patients who are known to be allergic to GPC3 imaging agents or synthetic excipients * 5: Fasting blood glucose levels exceeding 11.0 mmol/L before injection of 18F-FDG * 6: Individuals who are unable to complete PET/MR or PET/CT examinations (including inability to lie flat, claustrophobia, radiation phobia, etc.) * 7: Researchers believe that compliance is poor or there are other unfavorable factors for participating in this experiment
Where it's running
-
China, Hubei Province
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: Xiaoli Lan, PhD
- Email: lxl730724@hotmail.com
- Phone: 0086-027-83692633
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Candonilimab with Fruquintinib and Paclitaxel Albumin-Bound as second-line treatment for advanced gastric cancer
This phase 2 trial tests whether adding candonilimab to fruquintinib and nab-paclitaxel helps people with advanced gastric or gastroesophageal junction cancer who progressed after first-line therapy.
-
Pulse Wave vs Saline Bolus EIT to measure lung perfusion in ARDS
This study tests whether pulse wave EIT or saline bolus EIT can best show lung blood flow in ARDS patients on mechanical ventilation.
-
AI-powered CT help to guide pneumonia care
A multicenter trial tests whether using a chest CT–based AI report to guide care reduces death or need for new organ support in adults with pneumonia.
-
AI-assisted longitudinal CT to guide indeterminate lung nodules
This trial tests whether giving doctors an AI report that tracks nodules over serial CT scans helps reduce unnecessary benign lung resections in patients with indeterminate nodules.
-
Low-Dose CBCT AI Model for Interventions
This trial tests a low-dose CBCT AI model to guide image-guided interventional procedures for adults requiring CBCT during brain, lung, or liver interventions.
-
Dalpiciclib with an aromatase inhibitor and olmesartan as first-line therapy for HR+/HER2- advanced breast cancer
This trial tests whether adding dalpiciclib and olmesartan to an aromatase inhibitor helps people with HR+/HER2- advanced breast cancer respond to first-line treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.